Long term responses with cetuximab therapy in glioblastoma multiforme.

摘要

For those physicians involved in the care of patients with glioblastoma, it was a very long time from Walkers report in 19801 demonstrating the benefit of adding a nkrosourea 'to radiation until Stupp's report in 20052 confirming the benefit of daily temozolomide with radiation and continued temozolomide administration leading to an improved median and two year survival. The intervening period has been filled with numerous unsuccessful Phase I-III studies showing little progress. The recent advances in understanding the genetic makeup of glioblastoma as well as a better understanding of the underlying mechanisms of proliferation and progression have now opened numerous avenues of clinic research. We now have a host of approaches including direct placement of agents into the resection cavity as well as systemically administered agents including small molecule TKIs. Will systemically administered monoclonal antibodies be added to the list?